We also participated in several hair care product launches by some of our large multinational customers and several body lotion and spray products that are equipped with our dispensing systems that were launched in Russia, Poland and Thailand. Now looking at our pharma segment, strong demand for our nasal delivery devices from the prescription drug market was partially offset by weaker sales to the consumer healthcare market.
We’re particularly pleased that we began shipping from our new facility in Mumbai, India during the quarter as anticipated. Also it was an exciting quarter in terms of approvals of new drugs that are equipped with our delivery systems. There were a couple of approvals that happened in the quarter, that did not impact our results. But are important nonetheless as they relate to the debut of our patented dose indicator called Landmark.
Skyepharma’s Flutiform, a combination steroid treatment for asthma has been approved in Europe and is expected to be on the market before the end of the year. Flutiform is equipped with Aptar Pharma’s Landmark dose indicator and a metered dose valve. Also in nasal aerosol allergy treatment distributed by Sunovion Pharmaceuticals has been approved by the FDA and also uses our Landmark system. This treatment is planned to be on the market in the U.S. later in the third quarter just ahead of the fall of allergy season.
On the generic front, the FDA approved Sun Pharma’s generic Astelin Nasal Spray, which is equipped with our nasal delivery device and this again is expected to be on the market in the second half of 2012. We also have some several interesting consumer healthcare launches including a new eye moisturizing product in Europe that uses our preservative free pump. Several nasal saline launches in Brazil and Argentina, using our Bag-on-Valve system and in China several customers launched antiseptic sprays using various topical spray pumps of ours.Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV